Pharmaceutical Industry

Pharmaceutical industry payments to U.S. rheumatologists topped $220 million from 2014 through 2019, with 78% of that total going to just 6% of recipients, according to an analysis of CMS data published in Arthritis & Rheumatology.

Financial payments from pharmaceutical companies were “consistently associated with increased prescribing” across a wide range of physician specialties, drug classes and prescribing decisions, according to the authors of a recent review.

On July 24, President Donald Trump signed four executive orders intended to curb skyrocketing drug prices in the United States — notable among them was the plan to match prices for certain Medicare drugs to those offered in other countries.

A panel of pharmaceutical industry representatives highlighted potential hope on the horizon for COVID-19 vaccines and therapeutics during the 2020 Association of Women in Rheumatology National Conference.

It is quite possible that the attempt to treat COVID-19 will bear out as the peak of pharmaceutical research and development in human history.

Global adoption of a European Union regulation may improve the public image of and sentiment toward the pharmaceutical industry, according to research presented at the American Society of Clinical Psychopharmacology Annual Meeting.

The FDA and the Federal Trade Commission on Monday announced a partnership aimed at supporting the adoption of biosimilars and interchangeable products by deterring what they called “anti-competitive business practices,” such as false or misleading promotions, according to a joint statement.

Rising rates of stimulant prescribing may be partly influenced by pharmaceutical industry marketing to physicians, according to study findings published in JAMA Pediatrics.

Despite pressure from the Trump administration and Congress to curb rising drug costs, pharmaceutical companies — in what has become a common industry practice — have begun January 2020 by instituting a bevy of price increases.

NovaBay Pharmaceuticals reported a second quarter net loss of $2.5 million, or $0.14 per share, compared with a net loss of $1.6 million, or $0.09 per share, in the same period of 2018, according to a press release.